

## AUTHOR CONFLICT OF INTEREST STATEMENT

Every author publishing a CNE article must complete the entire form to comply with ANCC guidelines that all individuals authoring a continuing nursing education article disclose any conflict of interest.

Name and Credentials

### CONFLICT OF INTEREST STATEMENT

It is the responsibility of the continuing nursing education (CNE) division of the **Pediatric Nursing Journal (PNJ)** and its accredited body, the American Nurses Credentialing Center-Commission on Accreditation (ANCC-COA), to insure balance, independence, objectivity, and scientific rigor in all its approved CNE activities. All faculties participating in a PNJ-approved activity are expected to disclose to the audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the CE activity. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to your professional practice. This policy is not intended to prevent an article with a potential conflict of interest from being published however, any potential conflict should be identified openly, with full disclosure, so that the readers may form their own judgments about the material. The readers will determine for themselves whether outside interests may reflect a possible bias. This does not assume that the existence of these interests or commitments necessarily implies bias or decreases the value of your participation. This disclosure (see the section below) will be kept on file after submitted.

Authors who refer to commercial products (off-label, experimental and other) must abide by the following standards.

1. If an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the presenter must disclose that the product is not labeled for the use under discussion or that the product is still under investigation.
2. Authors' use of generic names will contribute to a balanced view of therapeutic options. If trade names are used, those of several companies should be used rather than only that a single supporting company.

### DISCLOSURE DECLARATION

I, or a family member, **have no** actual or potential conflict of interest in relation to the presentation within the past 12 months.

Signature:

Date:

I, or a family member, **have a** financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of a CE activity within the past 12 months. Please answer the questions below.

Signature:

Date:

**Affiliation / Financial Interest**

Self

Other

**Relationship:**

Grant/Research Support

Consultant Presenter Bureau

Major Stock Shareholder (not including mutual funds)

Advisory Board

Other Financial or Material Support

**Is there a discussion of unlabeled uses?**

**G Yes**

**G No**

If yes, please explain below. A disclosure will be printed with the published article.